Data / New clinical trials / Multiple Myeloma

Multiple Myeloma trials: 389 new since Nov 2024

Name: New Multiple Myeloma clinical trials
Creator: SpecStream
License: https://creativecommons.org/licenses/by/4.0/

The full list. New Multiple Myeloma clinical trials: 389 rows for $19.45, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. The list gains about 16 rows a month. The new rows come each week by email, $19 a month.

Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, enrollment type, location countries and 5 more), which open on your screen as soon as the payment clears and come by email. The weekly rows run until you cancel, from the link in each delivery. The rows on this page are a sample.

For agents and scripts: this list is ordered at https://specstream.ai/data/clinical-trials/condition/multiple-myeloma, and every list with its row count and price is at https://specstream.ai/data/lists.json.

Updated November 9, 2026. Source: ClinicalTrials.gov API v2 (U.S. National Library of Medicine).

389 clinical studies in Multiple Myeloma were first posted on ClinicalTrials.gov from November 15, 2024 to November 9, 2026; 112 have an industry sponsor and 343 are recruiting or about to. The newest, NCT07927023, was posted on November 9, 2026: A Study to Learn About a Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma (Pfizer).

The request: Every new Multiple Myeloma clinical trial on ClinicalTrials.gov, with the sponsor, phase, sites and the listed contact. $10 of credit on sign-up, no card.

Get new trials like these Watch a sponsor

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

389New trials
112Industry sponsored
343Recruiting or not yet
November 9, 2026Latest posted

Newest trials

The newest 100 of 389, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

First posted	NCT ID	Title	Sponsor	Phase	Status	Conditions	Enrollment	Countries	Source
November 9, 2026	NCT07927023	A Study to Learn About a Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma	Pfizer	Observational	Not yet recruiting	Multiple Myeloma	1		clinicaltrials.gov
November 3, 2026	NCT07914556	Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers	Mabwell (Shanghai) Bioscience Co., Ltd.	Phase 1	Recruiting	AML, Multiple Myeloma, CMML	122	China	clinicaltrials.gov
November 3, 2026	NCT07912684	The Value of a Tailored-based, Exercise Program for Improving Quality of Life of Patients With Hematologic Malignancies: a Pilot Randomized...	Gruppo Italiano Malattie EMatologiche dell'Adulto	Not applicable	Recruiting	Acute Myeloid Leukemia, Multiple Myeloma, Lymphoma	75	Italy	clinicaltrials.gov
November 3, 2026	NCT07911748	A Study of MBS314 for Injection in Participants With Relapsed/Refractory Multiple Myeloma.	Beijing Mabworks Biotech Co., Ltd.	Phase 1/2	Not yet recruiting	Multiple Myeloma	78		clinicaltrials.gov
November 2, 2026	NCT07910903	Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma	Keymed Biosciences Co.Ltd	Phase 3	Not yet recruiting	Multiple Myeloma (MM)	320	China	clinicaltrials.gov
October 30, 2026	NCT07907211	Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma	Chen Lijuan	Phase 4	Recruiting	Multiple Myeloma, Venous Thromboembolism (VTE)	200	China	clinicaltrials.gov
October 30, 2026	NCT07906418	BCMA Polymorphisms in Patients With Multiple Myeloma	Başakşehir Çam & Sakura City Hospital	Observational	Not yet recruiting	Multiple Myeloma	420	Turkey (Türkiye)	clinicaltrials.gov
October 29, 2026	NCT07903636	QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease	Institute of Hematology & Blood Diseases Hospital, China	Phase 2	Not yet recruiting	Multiple Myeloma (MM)	55	China	clinicaltrials.gov
October 29, 2026	NCT07903506	To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma	Kite, A Gilead Company	Phase 3	Not yet recruiting	Newly Diagnosed Multiple Myeloma	750		clinicaltrials.gov
October 29, 2026	NCT07903272	A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants...	Janssen Research & Development, LLC	Phase 3	Not yet recruiting	Multiple Myeloma	1,000		clinicaltrials.gov
October 28, 2026	NCT07901868	Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma	PETHEMA Foundation	Phase 2	Not yet recruiting	Multiple Myeloma Refractory, Multiple Myeloma in Relapse	60	Spain	clinicaltrials.gov
October 26, 2026	NCT07895017	Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell Cytopenias	University of Virginia	Phase 2	Not yet recruiting	Thrombocytopenia	26	United States	clinicaltrials.gov
October 23, 2026	NCT07891871	RE-RITE: Real-world Evaluation of Response, Implementation and Toxicity of Elranatamab	The Royal Wolverhampton Hospitals NHS Trust	Observational	Not yet recruiting	Myeloma Multiple	400		clinicaltrials.gov
October 22, 2026	NCT07887984	Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma	Alliance for Clinical Trials in Oncology	Phase 2/3	Not yet recruiting	Multiple Myeloma (MM)	920		clinicaltrials.gov
October 21, 2026	NCT07887672	A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma	Kite, A Gilead Company	Phase 3	Not yet recruiting	Newly Diagnosed Multiple Myeloma	600		clinicaltrials.gov
October 20, 2026	NCT07882069	Effect of ACTIVE-Care on Cancer-Related Fatigue, Hope, and Psychological Resilience in Adolescents With Acute Lymphoblastic Leukemia	Selcuk University	Not applicable	Completed	Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Adolescent, Resilience...	70	Turkey (Türkiye)	clinicaltrials.gov
October 19, 2026	NCT07881835	A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or...	Pfizer	Phase 4	Not yet recruiting	Relapsed/Refractory Multiple Myeloma, Multiple Myeloma	75		clinicaltrials.gov
October 14, 2026	NCT07874334	Phase 1a/b Study of GPRC5D CART Therapy in Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis	Hadassah Medical Organization	Phase 1	Not yet recruiting	Relapsed/Refractory Multiple Myeloma (RRMM), Light-Chain Amyloidosis	160	Israel	clinicaltrials.gov
October 13, 2026	NCT07871747	Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART)	University of Chicago	Phase 1	Not yet recruiting	Lymphoma, B-Cell, Multiple Myeloma	32	United States	clinicaltrials.gov
October 2, 2026	NCT07855718	Serum Soluble BCMA as a Non-Invasive Marker in Multiple Myeloma	Assiut University	Observational	Not yet recruiting	Multiple Myeloma	90		clinicaltrials.gov
October 1, 2026	NCT07851493	Exercise Phenotyping Prior to Chemotherapy in Newly Diagnosed Multiple Myeloma (MM-Exercise)	Technical University of Munich	Observational	Recruiting	Exercise Behavior, Multiple Myeloma	80	Germany	clinicaltrials.gov
September 30, 2026	NCT07850284	SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders	Mayo Clinic	Observational	Recruiting	AL Amyloidosis, Multiple Myeloma	150	United States	clinicaltrials.gov
September 30, 2026	NCT07848672	Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell Mobilization	The Affiliated People's Hospital of Ningbo University	Phase 2/3	Not yet recruiting	Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization...	70		clinicaltrials.gov
September 25, 2026	NCT07842198	Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy	Zealand University Hospital	Phase 2	Not yet recruiting	Large B-Cell Lymphoma (LBCL), Multiple Myeloma (MM), Gut Microbiota	150	Denmark	clinicaltrials.gov
September 22, 2026	NCT07833046	Long-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F Injection	RenJi Hospital	Observational	Enrolling by invitation	Multiple Myeloma	40	China	clinicaltrials.gov
September 21, 2026	NCT07831122	Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)	Canadian Myeloma Research Group	Phase 1	Not yet recruiting	Relapsed Refractory Multiple Myeloma (RRMM)	108	Canada	clinicaltrials.gov
September 21, 2026	NCT07830485	CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma	Institute of Hematology & Blood Diseases Hospital, China	Phase 2	Not yet recruiting	Multiple Myeloma	24	China	clinicaltrials.gov
September 18, 2026	NCT07828522	F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma	Institute of Hematology & Blood Diseases Hospital, China	Phase 2	Not yet recruiting	Multiple Myeloma (MM), Transplant-eligible Patients	10		clinicaltrials.gov
September 17, 2026	NCT07825064	Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously...	Hoffmann-La Roche	Phase 2	Recruiting	Multiple Myeloma	45	Germany	clinicaltrials.gov
September 17, 2026	NCT07823959	CBC-Based Inflammatory Indices in Newly Diagnosed Multiple Myeloma	Assiut University	Observational	Not yet recruiting	Multiple Myeloma	60		clinicaltrials.gov
September 10, 2026	NCT07814170	A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In Greece	University of West Attica	Not applicable	Active not recruiting	Blood Cancers, Leukemia, Lymphoma, Bone Marrow Transplant, Psychological Trauma, Neoplasms, Hematological Malignancies...	80	Greece	clinicaltrials.gov
September 10, 2026	NCT07811986	HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease	Institute of Hematology & Blood Diseases Hospital, China	Phase 2	Not yet recruiting	Multiple Myeloma (MM)	20	China	clinicaltrials.gov
September 9, 2026	NCT07809594	CS1-Targeted CAR-T Cells for Relapsed/Refractory Multiple Myeloma	Institute of Hematology & Blood Diseases Hospital, China	Phase 1	Active not recruiting	Relapsed/Refractory Multiple Myeloma (RRMM), Plasma Cell Myeloma	10	China	clinicaltrials.gov
August 27, 2026	NCT07789522	Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple Myeloma	Institute of Hematology & Blood Diseases Hospital, China	Phase 2	Not yet recruiting	Multiple Myeloma (MM)	15		clinicaltrials.gov
August 25, 2026	NCT07785505	Musculoskeletal Ultrasound in Patients With Hematologic Malignancies	Assiut University	Observational	Not yet recruiting	Hematologic Neoplasms, Leukemia, Lymphoma, Multiple Myeloma, Musculoskeletal Diseases	50		clinicaltrials.gov
August 25, 2026	NCT07783607	MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma	University of Vermont Medical Center	Not applicable	Not yet recruiting	Multiple Myeloma, Heart Disease Risk Factors	33	United States	clinicaltrials.gov
August 24, 2026	NCT07782944	CD38 Targeted -PET/ CT for Multiple Myeloma	Guilin Medical University, China	Not applicable	Recruiting	Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma	100	China	clinicaltrials.gov
August 20, 2026	NCT07777406	Real-life Study on the Use of Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Relapsed/Refractory Multiple Myeloma	Università degli Studi 'G. d'Annunzio' Chieti e Pescara	Observational	Recruiting	Plasma Cell Neoplasms	60	Italy	clinicaltrials.gov
August 20, 2026	NCT07776964	Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE)	University of Minnesota	Not applicable	Not yet recruiting	Cardiotoxicity, Cancer, Cardiac Arrhythmia, Left Ventricular Dysfunction, Breast Cancer, Multiple Myeloma	72	United States	clinicaltrials.gov
August 19, 2026	NCT07774988	Individualized Education for Bortezomib-Related Symptom Management in Multiple Myeloma	Can Lafci	Not applicable	Completed	Multiple Myeloma	49	Turkey (Türkiye)	clinicaltrials.gov
August 18, 2026	NCT07771361	BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma	Luminary Therapeutics	Phase 2	Not yet recruiting	Non-Hodgkin Lymphoma Refractory/ Relapsed, Multiple Myeloma Refractory, Multiple Myeloma in Relapse, Non-Hodgkin...	90		clinicaltrials.gov
August 14, 2026	NCT07764978	Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT	AstraZeneca	Phase 3	Recruiting	Newly Diagnosed Multiple Myeloma	750	Australia, Brazil, Canada, Denmark, France, Germany, Italy, Japan, Poland...	clinicaltrials.gov
August 14, 2026	NCT07764861	A Open-Label Phase in Participants With Multiple Myeloma	Innovent Biologics (Suzhou) Co. Ltd.	Phase 2	Not yet recruiting	Multiple Myeloma	120	China	clinicaltrials.gov
August 13, 2026	NCT07763054	Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients	Haikou Affiliated Hospital of Central South University Xiangya School of Medicine	Observational	Recruiting	Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Lymphoma, Multiple Myeloma, Chronic...	30	China	clinicaltrials.gov
August 12, 2026	NCT07760454	A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma	UCARsgen Biotech Limited	Phase 1/2	Recruiting	Relapsed/Refractory Multiple Myeloma	68	China	clinicaltrials.gov
August 12, 2026	NCT07759102	Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple Myeloma	University of California, Davis	Phase 1	Not yet recruiting	Recurrent Multiple Myeloma, Refractory Multiple Myeloma	20	United States	clinicaltrials.gov
August 11, 2026	NCT07757412	Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple...	Odense University Hospital	Phase 2	Not yet recruiting	Multiple Myeloma Progression	50	Denmark, Estonia, Finland, Norway	clinicaltrials.gov
August 7, 2026	NCT07751783	Development and Dissemination of Exercise Prescription and Intervention for Cancer Populations	Kaohsiung Medical University Chung-Ho Memorial Hospital	Not applicable	Recruiting	Cancer, Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Lung Cancer...	150	Taiwan	clinicaltrials.gov
August 6, 2026	NCT07748689	Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple...	Polish Myeloma Consortium	Phase 2	Not yet recruiting	Relapsed / Refractory Multiple Myeloma	228		clinicaltrials.gov
August 4, 2026	NCT07746232	Validating DW-MRI and Fat Fraction in Multiple Myeloma Post-ASCT: The RAC-FAT Study"	Fondazione EMN Italy Onlus	Observational	Not yet recruiting	Multiple Myeloma (MM)	92	Italy	clinicaltrials.gov
August 3, 2026	NCT07742527	A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma...	GlaxoSmithKline	Phase 1	Not yet recruiting	Multiple Myeloma	22		clinicaltrials.gov
August 3, 2026	NCT07742215	A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma...	Biocad	Phase 3	Recruiting	Myeloma Multiple	390	Belarus, Russia	clinicaltrials.gov
July 31, 2026	NCT07740486	A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After...	Polish Myeloma Consortium	Phase 3	Not yet recruiting	Multiple Myeloma (MM)	248		clinicaltrials.gov
July 31, 2026	NCT07740317	Neurocognitive Trajectories After BCMA CAR-T	Wake Forest University Health Sciences	Observational	Recruiting	Multiple Myeloma (MM), CART Therapy, Refractory Multiple Myeloma (RRMM)	50	United States	clinicaltrials.gov
July 30, 2026	NCT07735637	A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed...	AstraZeneca	Phase 3	Recruiting	Newly Diagnosed Multiple Myeloma (NDMM)	750	Australia, Brazil, Canada, China, Denmark, France, Germany, Italy, Japan...	clinicaltrials.gov
July 30, 2026	NCT07735546	A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma	Umoja Biopharma	Phase 1	Not yet recruiting	Multiple Myeloma in Relapse, Multiple Myeloma (MM)	100		clinicaltrials.gov
July 29, 2026	NCT07732712	Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells	The Affiliated People's Hospital of Ningbo University	Phase 2/3	Not yet recruiting	Multiple Myeloma	15		clinicaltrials.gov
July 27, 2026	NCT07728188	A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies...	AbbVie	Phase 3	Not yet recruiting	Relapsed or Refractory Multiple Myeloma	520	Australia, Canada, France, Germany, Hungary, Italy, Netherlands, Norway...	clinicaltrials.gov
July 27, 2026	NCT07727668	Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for...	Shambavi Richard	Early phase 1	Not yet recruiting	Multiple Myeloma, Relapsed/Refractory Multiple Myeloma	22	United States	clinicaltrials.gov
July 24, 2026	NCT07726160	A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple Myeloma	Institute of Hematology & Blood Diseases Hospital, China	Phase 1	Not yet recruiting	Relapse and/or Refractory Multiple Myeloma	30	China	clinicaltrials.gov
July 24, 2026	NCT07725406	Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma	Weill Medical College of Cornell University	Phase 1	Recruiting	Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM)	32	United States	clinicaltrials.gov
July 23, 2026	NCT07721350	Prospective Evaluation of Subcutaneous Administration of Daratumumab by the FreedomEDGE® Infusion System	Hospices Civils de Lyon	Not applicable	Not yet recruiting	Multiple Myeloma or Amyloidosis	100	France	clinicaltrials.gov
July 22, 2026	NCT07720843	TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)	Montefiore Medical Center	Phase 1	Not yet recruiting	Relapse Multiple Myeloma, Refractory Multiple Myeloma	50		clinicaltrials.gov
July 20, 2026	NCT07715630	In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma	Chongqing Precision Biotech Co., Ltd	Phase 1	Recruiting	Relapsed or Refractory Multiple Myeloma (RRMM)	15	China	clinicaltrials.gov
July 20, 2026	NCT07713511	INfections in Patients Treated With CAR-T	IRCCS Azienda Ospedaliero-Universitaria di Bologna	Observational	Not yet recruiting	Relapsed Multiple Myeloma, Refractory Multiple Myeloma, B-Cell Non-Hodgkin Lymphoma, Bloodstream Infections, CAR-T Cell...	290	Italy	clinicaltrials.gov
July 15, 2026	NCT07705074	FAPI PET Imaging - An Exploratory Study	Martin Huellner	Phase 1/2	Not yet recruiting	Thyroid Pathology, Head and Neck Cancer (H&N), Sinonasal Tract Tumor, Sarcoidosis, Thyroid Cancer, Breast Cancer...	770	Switzerland	clinicaltrials.gov
July 10, 2026	NCT07695740	Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma	Excyte Biopharma Ltd	Phase 2	Not yet recruiting	Relapsed or Refractory Multiple Myeloma (RRMM)	64	China	clinicaltrials.gov
July 8, 2026	NCT07691034	Monitoring MRD in Multiple Myeloma in Serum by Mass Spectrometry	Odense University Hospital	Observational	Not yet recruiting	Multiple Myeloma, Minimal Residual Disease	40		clinicaltrials.gov
July 8, 2026	NCT07689058	CAR-T in Relapsed/Refractory Multiple Myeloma	Dr. Zaineb Akram	Phase 2	Recruiting	Multiple Myeloma Refractory, Multiple Myeloma in Relapse	10	Pakistan	clinicaltrials.gov
July 7, 2026	NCT07689006	Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens	Bristol-Myers Squibb	Observational	Completed	Relapsed/Refractory Multiple Myeloma	341	United States	clinicaltrials.gov
July 7, 2026	NCT07687004	Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification	Institute of Hematology & Blood Diseases Hospital, China	Phase 1/2	Not yet recruiting	Multiple Myeloma (MM)	50	China	clinicaltrials.gov
July 6, 2026	NCT07684274	Early Screening for Multiple Myeloma Based on Liquid Biopsy cfDNA Fragmentomics	The First Affiliated Hospital with Nanjing Medical University	Observational	Not yet recruiting	Multiple Myeloma (MM), Smoldering Multiple Myeloma (SMM), MGUS	290		clinicaltrials.gov
July 2, 2026	NCT07681596	A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma	AstraZeneca	Phase 1/2	Recruiting	Relapsed or Refractory Multiple Myeloma	101	Australia, United States	clinicaltrials.gov
July 1, 2026	NCT07679919	BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies	Luminary Therapeutics	Phase 1	Not yet recruiting	Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia, Multiple Myeloma	27	United States	clinicaltrials.gov
June 29, 2026	NCT07674498	Immune Fitness in Older Patients With Relapsed and Refractory Multiple Myeloma	Jules Bordet Institute	Not applicable	Recruiting	Myeloma Multiple	31	Belgium	clinicaltrials.gov
June 26, 2026	NCT07671287	GMMG-HD11/DSMM XXI/64007957MMY3010	University of Heidelberg Medical Center	Phase 3	Not yet recruiting	Multiple Myeloma	399		clinicaltrials.gov
June 25, 2026	NCT07667868	A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple...	BrightPath Biotherapeutics Co., Ltd.	Phase 1	Not yet recruiting	Relapsed/Refractory Multiple Myeloma (RRMM)	18		clinicaltrials.gov
June 24, 2026	NCT07665450	A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide...	Janssen Research & Development, LLC	Phase 3	Recruiting	Multiple Myeloma	1,000	Australia, Czechia, France, Germany, Greece, Israel, Italy, Netherlands...	clinicaltrials.gov
June 24, 2026	NCT07665307	Delayed Toxicities Post-CAR-T	Icahn School of Medicine at Mount Sinai	Observational	Recruiting	Multiple Myeloma	30	United States	clinicaltrials.gov
June 23, 2026	NCT07663253	Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients	Shanghai Zhongshan Hospital	Observational	Recruiting	Multiple Myeloma	333	China	clinicaltrials.gov
June 22, 2026	NCT07660939	GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders	Peking University First Hospital	Phase 1	Recruiting	Plasma Cell Disorders, Multiple Myeloma (MM)	50	China	clinicaltrials.gov
June 18, 2026	NCT07657312	Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory...	Naresh Bumma	Phase 2	Recruiting	Cytokine Release Syndrome, Recurrent Multiple Myeloma, Refractory Multiple Myeloma	35	United States	clinicaltrials.gov
June 17, 2026	NCT07652281	A Clinical Study of SHR-5421 in Patients With Multiple Myeloma	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	Phase 1	Recruiting	Multiple Myeloma	97	China	clinicaltrials.gov
June 16, 2026	NCT07649681	Gustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition Intervention	Wuerzburg University Hospital	Not applicable	Recruiting	Multiple Myeloma (MM), GI Cancer, Taste Disorder, Melanoma (Skin Cancer), Urogenital Cancers	198	Germany	clinicaltrials.gov
June 16, 2026	NCT07649525	Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level	University of Leeds	Phase 3	Recruiting	Multiple Myeloma (MM), Plasma Cell Leukemia (PCL)	1,226	United Kingdom	clinicaltrials.gov
June 15, 2026	NCT07648459	CM336-SOC for Dynamically High-Risk Multiple Myeloma Study	Institute of Hematology & Blood Diseases Hospital, China	Phase 2	Not yet recruiting	Multiple Myeloma	46		clinicaltrials.gov
June 15, 2026	NCT07648264	Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting...	CSL Behring	Phase 3	Recruiting	Secondary Immune Deficiency	63	Belgium, Canada, Czechia, Denmark, France, Germany, Italy, Poland, Spain...	clinicaltrials.gov
June 15, 2026	NCT07646873	PET-Enabled Dual-Energy CT in Multiple Myeloma	University of California, Davis	Not applicable	Not yet recruiting	Multiple Myeloma (MM)	45	United States	clinicaltrials.gov
June 11, 2026	NCT07642362	Digital Support for Multiple Myeloma Quality of Life	CareAcross	Not applicable	Recruiting	Multiple Myeloma, Patient Reported Outcome (PRO), Supportive Care in Cancer, Quality of Life	108	Greece	clinicaltrials.gov
June 10, 2026	NCT07638683	A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple...	Shanghai Zhongshan Hospital	Phase 2	Recruiting	Multiple Myeloma, AL Amyloidosis	30	China	clinicaltrials.gov
June 10, 2026	NCT07637578	A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma	SCRI Development Innovations, LLC	Phase 2	Recruiting	Multiple Myeloma (MM), Multiple Myeloma Refractory, Multiple Myeloma in Relapse, Multiple Myeloma	46	United States	clinicaltrials.gov
June 8, 2026	NCT07634263	Why Patients Decline or Are Being Deemed Ineligible to Receive Home-based Treatment: a Mixed Methods Study	Odense University Hospital	Observational	Not yet recruiting	Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Multiple Myeloma Progression, Multiple...	50	Denmark	clinicaltrials.gov
June 5, 2026	NCT07628595	Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma	The First Affiliated Hospital with Nanjing Medical University	Early phase 1	Not yet recruiting	Multiple Myeloma (MM)	19	China	clinicaltrials.gov
June 3, 2026	NCT07624760	Early Detection of Amyloidosis in Monoclonal Gammopathy Using Nuclear Medicine Imaging	University of Zurich	Not applicable	Not yet recruiting	Monoclonal Gammopathy, Monoclonal Gammopathy of Undetermined Significance (MGUS), Multiple Myeloma, AL Amyloidosis...	50	Switzerland	clinicaltrials.gov
June 3, 2026	NCT07624513	D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM	Dana-Farber Cancer Institute	Phase 3	Recruiting	Multiple Myeloma	720	United States	clinicaltrials.gov
June 3, 2026	NCT07623798	A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003	Innovent Biologics (Suzhou) Co. Ltd.	Phase 3	Recruiting	Relapsed or Refractory Multiple Myeloma	255	China	clinicaltrials.gov
June 2, 2026	NCT07620275	Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA	Chinese PLA General Hospital	Phase 1	Recruiting	Multiple Myeloma	9	China	clinicaltrials.gov
May 29, 2026	NCT07614360	Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With...	GlaxoSmithKline	Phase 2	Not yet recruiting	Multiple Myeloma	150		clinicaltrials.gov
May 29, 2026	NCT07614243	Long Non-coding RNA (lncRNA) ZFAS1-Mediated Mechanism of Roasted Nux Vomica in Intervening Bortezomib-Induced Peripheral Neuropathy	The First Affiliated Hospital of Zhejiang Chinese Medical University	Not applicable	Completed	Multiple Myeloma, Chemotherapy-Induced Peripheral Neuropathy	22	China	clinicaltrials.gov
May 29, 2026	NCT07612787	A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma	Centre Hospitalier Universitaire de Saint Etienne	Phase 1/2	Not yet recruiting	Myeloma Multiple	44	France	clinicaltrials.gov

Sponsors posting most

Sponsor	New trials	Latest
Institute of Hematology & Blood Diseases Hospital, China	25	October 29, 2026
GlaxoSmithKline	12	August 3, 2026
Janssen Research & Development, LLC	8	October 29, 2026
AbbVie	6	July 27, 2026
Memorial Sloan Kettering Cancer Center	6	March 6, 2026
Xuzhou Medical University	6	July 17, 2025
Mayo Clinic	5	September 30, 2026
AstraZeneca	5	August 14, 2026
National Cancer Institute (NCI)	5	March 30, 2026
Gruppo Italiano Malattie EMatologiche dell'Adulto	4	November 3, 2026
Odense University Hospital	4	August 11, 2026
IRCCS Azienda Ospedaliero-Universitaria di Bologna	4	July 20, 2026
The First Affiliated Hospital with Nanjing Medical University	4	July 6, 2026
Regeneron Pharmaceuticals	4	May 27, 2026
Qilu Pharmaceutical Co., Ltd.	4	February 10, 2026
Medical College of Wisconsin	4	November 19, 2025
Washington University School of Medicine	4	November 12, 2025
The First Affiliated Hospital of Soochow University	4	June 12, 2025
Pfizer	3	November 9, 2026
Assiut University	3	October 2, 2026

By phase

Phase	New trials	Latest
Not applicable	71	November 3, 2026
Phase 2	67	October 29, 2026
Phase 1	65	November 3, 2026
Observational	64	November 9, 2026
Phase 1/2	41	November 3, 2026
Phase 3	37	November 2, 2026
Early phase 1	25	July 27, 2026
Phase 4	11	October 30, 2026
Phase 2/3	8	October 22, 2026

By country

Country	New trials	Latest
China	116	November 3, 2026
United States	114	October 26, 2026
France	34	August 14, 2026
Italy	32	November 3, 2026
Germany	28	October 1, 2026
Spain	26	October 28, 2026
Australia	25	August 14, 2026
Canada	20	September 21, 2026
South Korea	18	August 14, 2026
Japan	17	August 14, 2026
United Kingdom	16	August 14, 2026
Greece	15	September 10, 2026
Poland	15	August 14, 2026
Norway	15	August 11, 2026
Israel	13	October 14, 2026
Brazil	12	August 14, 2026
Denmark	11	September 25, 2026
Netherlands	11	July 27, 2026
Taiwan	10	August 14, 2026
Turkey (Türkiye)	8	October 30, 2026
Sweden	8	August 14, 2026
Belgium	6	June 29, 2026
Czechia	6	June 24, 2026
Portugal	5	July 27, 2026
Switzerland	4	July 15, 2026

Where the register publishes

U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.